January #55 : Glaxo Makes a Deal - by Jay Blotcher

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Work 2000

Take This Job & Love it!

POZ Work

Editor's Letter


Glaxo Makes a Deal

For Whom the Nobel Tolls

Homesick Blues


"Dutch" Treat

Eye of the Beholder

Shout Out

LA Women

Missing Persons Report

Catching Up With Michael Johnston


Oink, Oink

A Define Mess

Do Ask, Do Tell

Primary Colors

A Modest Proposal

Portrait of the Artist as a Sex Bomb

Play It As It Lays

Beginner's Luck

Follow Your Heart

Next Up...The lowdown on what’s inside the pipeline

Stool's Gold

Comfort Zone

Wart's Up, Nurse?

Herb of the Month

Cancer Answers

Watch Your Hep

Boys' Night Out

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

January 2000

Glaxo Makes a Deal

by Jay Blotcher

Drug company goliath Glaxo Wellcome PLC took a hit in October from the postmodern slingshot: a lawsuit. In an out-of-court settlement, Glaxo acknowledged that partial credit for the development of abacavir (Ziagen) goes to the University of Minnesota (UM), which now stands to be compensated with up to $300 million in drug-sale royalties.

The university sued Glaxo in October 1998—two months before Ziagen was granted accelerated FDA approval—when UM officials learned that Glaxo would not honor a licensing agreement hammered out by both parties in 1992. UM charged that the drug was made with a synthetic molecule devised by UM chemists Robert Vince, PhD, and Mei Hua, PhD, in the ’70s. Glaxo countered that the drug was invented by Glaxo scientist Susan Daluge, a former postdoctoral student of Vince’s, who Glaxo said made the discovery apart from her UM research.

UM wanted not only to protect its intellectual property, according to Vince, but to reap the fruits of its labors, estimated to be in the millions. Ziagen, a nucleoside analog reverse transcriptase inhibitor taken twice daily in combination with other drugs, had a big industry buzz from the start. The settlement calls for Glaxo to pay the university royalties up to 10 percent of sales above $700 million.

“We knew we had a good case, but we didn’t expect to settle so quickly,” Vince told POZ. UM plans to launch a drug-development center with its windfall. Vince, who will receive a third of the funds, will create an endowment fund to support other colleagues’ work. Asked what he learned from dealing with big-business Glaxo, Vince mused: “I’m a scientist—that’s why I don’t work for a pharmaceutical company. No one tells me who my friends are or who I can talk to. Academic scientists, we talk too much—we’re not trying to make a profit.”  

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.